Comparison of Two Combinations of Maximum Medical Therapy for Lowering Intraocular Pressure in Primary Open-angle Glaucoma
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: We sought to compare the efficacy as well as the safety of two maximum medical therapy combinationsapplied to lower the intraocular pressure (IOP) in different primary open-angle glaucoma (POAG) agegroups. Methods: This was a retrospective, consecutive case series study that included 60 eyes of 60 subjects withPOAG, specifically 20 subjects aged 40 to 54 years, 21 aged 55 to 69 years, and 19 aged 70 years or older. All had been treated for at least 12 months with triple maximum medical therapy (TMT; dorzolamide/timolol,brimonidine, and latanoprost) to lower their IOP, which subsequently was changed to double maximum medicaltherapy (DMT, fixed drug combinations of tafluprost/timolol and brinzolamide/brimonidine). The rate of IOPchange and adverse drug reactions were compared amongst the three age groups. Results: The mean IOP change at three months after converting from TMT to DMT was -0.65 ± 1.42 mmHg(-3.84% ± 9.31%) among the overall study group, but this finding was not statistically significant (p = 0.108). Inthe 40 to 54 years and 55 to 69 years groups, the mean IOP change rates were +0.29 ± 0.96 mmHg (+2.40%± 6.85%, p = 0.087) and -0.50 ± 0.99 mmHg (-3.05% ± 6.40%, p = 0.084) respectively. In the 70 years or oldergroup, the mean IOP change, interestingly, was -1.80 ± 1.46 mmHg (-11.29% ± 9.31%, p < 0.001) and nine (47.4%)of the 19 subjects showed additional IOP reductions of 10% or more after converting from TMT to DMT. In allthree age groups, the incidence rate of dry eye was significantly lower for DMT than for TMT (p = 0.031). Conclusions: In POAG patients, DMT was proven to be both effective and safe for lowering the IOP, especiallyin those 70 years or older group, when compared with the TMT protocol.
Abstract
Purpose: We sought to compare the efficacy as well as the safety of two maximum medical therapy combinationsapplied to lower the intraocular pressure (IOP) in different primary open-angle glaucoma (POAG) agegroups. Methods: This was a retrospective, consecutive case series study that included 60 eyes of 60 subjects withPOAG, specifically 20 subjects aged 40 to 54 years, 21 aged 55 to 69 years, and 19 aged 70 years or older. All had been treated for at least 12 months with triple maximum medical therapy (TMT; dorzolamide/timolol,brimonidine, and latanoprost) to lower their IOP, which subsequently was changed to double maximum medicaltherapy (DMT, fixed drug combinations of tafluprost/timolol and brinzolamide/brimonidine). The rate of IOPchange and adverse drug reactions were compared amongst the three age groups. Results: The mean IOP change at three months after converting from TMT to DMT was -0.65 ± 1.42 mmHg(-3.84% ± 9.31%) among the overall study group, but this finding was not statistically significant (p = 0.108). Inthe 40 to 54 years and 55 to 69 years groups, the mean IOP change rates were +0.29 ± 0.96 mmHg (+2.40%± 6.85%, p = 0.087) and -0.50 ± 0.99 mmHg (-3.05% ± 6.40%, p = 0.084) respectively. In the 70 years or oldergroup, the mean IOP change, interestingly, was -1.80 ± 1.46 mmHg (-11.29% ± 9.31%, p < 0.001) and nine (47.4%)of the 19 subjects showed additional IOP reductions of 10% or more after converting from TMT to DMT. In allthree age groups, the incidence rate of dry eye was significantly lower for DMT than for TMT (p = 0.031). Conclusions: In POAG patients, DMT was proven to be both effective and safe for lowering the IOP, especiallyin those 70 years or older group, when compared with the TMT protocol.
참고문헌 (28)
- "European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 3: Treatment principles and options Supported by the EGS Foundation: Part 1:Foreword; Introduction; Glossary; Chapter 3 Treatment principles and options", Br J Ophthalmol, 101, pp.130~195 (2017)
- "The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators", Am J Ophthalmol, 130, pp.429~440 (2000)
- Leske MC, "Factors for glaucoma progression and the effect of treatment : the early manifest glaucoma trial", Arch Ophthalmol, 121, pp.48~56 (2003)
- Kass MA, "The Ocular Hypertension Treatment Study : a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma", Arch Ophthalmol, 120, pp.701~713 (2002)
- Friedman DS, "Variations in treatment among adult-onset open-angle glaucoma patients", Ophthalmology, 112, pp.1494~1499 (2005)
- Webers CA, "Pharmacological management of primary open-angle glaucoma : second-line options and beyond", Drugs Aging, 25, pp.729~759 (2008)
- Quigley HA, "Risk factors for the development of glaucomatous visual field loss in ocular hypertension", Arch Ophthalmol, 112, pp.644~649 (1994)
- Inoue K, "Effectiveness and safety of switching from prostaglandin analog monotherapy to prostaglandin", timolol fixed combination therapy or adding ripasudil, 2018, pp.62, 508~516
- Barnebey HS, "The safety and efficacy of travoprost 0.004%", timolol 0.5% fixed combination ophthalmic solution, 2005, pp.140, 1~7
- Lee AJ, "Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure", Clin Ophthalmol, 2, pp.545~555 (2008)
- Seong GJ, "Comparisons of intraocular-pressure-lowering efficacy and side effects of 2% dorzolamide and 1% brinzolamide", Ophthalmologica, 215, pp.188~191 (2001)
- Uusitalo H, "Phase III Study Investigators. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study", Acta Ophthalmol, 88, pp.12~19 (2010)
- Uusitalo H, "Benefits of switching from latanoprost to preservative-free tafluprost eye drops : a meta-analysis of two Phase IIIb clinical trials", Clin Ophthalmol, 10, pp.445~454 (2016)
- Ikeda Y, "Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and taf luprost in Japanese with normal-tension glaucoma", Clin Ophthalmol, 10, pp.1633~1637 (2016)
- Suzuki K, "Multicenter, randomized, controlled study comparing tafluprost", timolol fixed combination with latanoprost, Adv Ther, pp.2018, 35[DOI]
- Mundorf T, "A 3-month comparison of efficacy and safety of brimonidine-purite 0.15%and brimonidine 0.2% in patients with glaucoma or ocular hypertension", J Ocul Pharmacol Ther, 19, pp.37~44 (2003)
- Kim CY, "Brimonidine 0.2% versus brimonidine Purite 0.15% in Asian ocular hypertension", J Ocul Pharmacol Ther, 23, pp.481~486 (2007)
- Katz LJ, "Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension", J Glaucoma, 11, pp.119~126 (2002)
- Joh HJ, "Comparison of different combinations of maximum medical therapy for lowering intraocular pressure in primary open angle glaucoma : 12-month retrospective consecutive case series", Jpn J Ophthalmol, 63, pp.322~327 (2019)
- Broadway DC, "Pharmacotherapy and adherence issues in treating elderly patients with glaucoma", Drugs Aging, 32, pp.569~581 (2015)
- Winfield AJ, "A study of the causes of non-compliance by patients prescribed eyedrops", Br J Ophthalmol, 74, pp.477~480 (1990)
- Lacey J, "Barriers to adherence with glaucoma medications: a qualitative research study", Eye (Lond), 23, pp.924~932 (2009)
- Jin H, "Factors affecting medication adherence in elderly people", Patient Prefer Adherence, 10, pp.2117~2125 (2016)
- Lockington D, "Free radicals and the pH of topical glaucoma medications: a lifetime of ocular chemical injury?", Eye (Lond), 26, pp.734~741 (2012)
- Manni G, "The safety and efficacy of brinzolamide 1%", timolol 0.5% fixed combination versus dorzolamide 2%, J Glaucoma, pp.2009, 18[DOI]
- Mundorf TK, "A patient preference comparison of Azarga(brinzolamide", timolol fixed combination)vs Cosopt(dorzolamide, Clin Ophthalmol, pp.2008, 2[DOI]
- Noecker RJ, "Corneal and conjunctival changes caused by commonly used glaucoma medications", Cornea, 23, pp.490~496 (2004)
- Mundorf T, "Evaluation of the comfort of Alphagan P compared with Alphagan in irritated eyes", Adv Ther, 20, pp.329~336 (2003)